Cat. No.: HY-N6856

4-Hydroxycoumarin

Name: 4-Hydroxycoumarin
Brand: MedChemExpress
SKU: HY-N6856
Price: 25.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Avis client

Based on 1 Customer Validation

4-Hydroxycoumarin is an orally active coumarin derivative, one of the most versatile heterocyclic scaffolds, often used in the synthesis of various organic compounds. 4-Hydroxycoumarin possesses both electrophilic and nucleophilic properties. 4-Hydroxycoumarin is an HIV protease inhibitor and tyrosine kinase inhibitor. 4-Hydroxycoumarin has anti-inflammatory, antibacterial and anti-tumor effects.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.96%
CAS No.: 1076-38-6
Formule: C₉H₆O₃
Masse moléculaire:162.14

Stockage:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

4-Hydroxycoumarin Chemical Structure

CAS No.: 1076-38-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (2)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
B16-F10	IC₅₀	70.74 μM Compound: 222-1	Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability	[PMID: 30594028]
EA.hy 926	EC₅₀	>200 μM Compound: 3, 4-HC	Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24721833]
EA.hy 926	EC₅₀	>200 μM Compound: 3, 4-HC	Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 24721833]
LNCaP	EC₅₀	100.51 μM Compound: 3, 4-HC	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24721833]
LNCaP	EC₅₀	120.27 μM Compound: 3, 4-HC	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 24721833]
MCF7	EC₅₀	>200 μM Compound: 3, 4-HC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24721833]
MCF7	EC₅₀	199.82 μM Compound: 3, 4-HC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 24721833]
MCF7	GI₅₀	95.34 μM Compound: 4a	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]
MDA-MB-231	EC₅₀	>200 μM Compound: 3, 4-HC	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24721833]
MDA-MB-231	EC₅₀	100.26 μM Compound: 3, 4-HC	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 24721833]
MDA-MB-231	IC₅₀	>100 μM Compound: 21.4	Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay	[PMID: 38340509]
MDA-MB-231	IC₅₀	>=100 μM Compound: Hydroxycoumarin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under hypoxia condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under hypoxia condition by MTT assay	[PMID: 38283214]
MDA-MB-231	IC₅₀	>=100 μM Compound: Hydroxycoumarin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under normoxia condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs under normoxia condition by MTT assay	[PMID: 38283214]
M-HeLa	IC₅₀	>=14.7 μM Compound: 102a	Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay	[PMID: 36481599]
PC-3	EC₅₀	150.46 μM Compound: 3, 4-HC	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24721833]
PC-3	EC₅₀	173.31 μM Compound: 3, 4-HC	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 24721833]
SK-MEL-28	IC₅₀	1.3 μM Compound: 9	Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
SK-MEL3	IC₅₀	2.1 μM Compound: 9	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37197457]
TK-10	GI₅₀	>100 μM Compound: 4a	Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]
U-937	EC₅₀	>200 μM Compound: 3, 4-HC	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by Alamar blue assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by Alamar blue assay	[PMID: 24721833]
U-937	EC₅₀	164.12 μM Compound: 3, 4-HC	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay	[PMID: 24721833]
UACC-62	GI₅₀	83.6 μM Compound: 4a	Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28041801]

In Vitro

4-Hydroxycoumarin (0, 50, 160, 500 μM, 24 h) disrupts the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts. However, they can reduce their adhesion and motility to extracellular matrix proteins^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[2]

View Protocol

Cell Line:

B16-F10, B82
Concentration:

0, 50, 160, 500 μM
Incubation Time:

24 h
Result:

Had no appreciable effect on cell viability.

Western Blot Analysis ^[2]

View Protocol

Cell Line:

B16-F10
Concentration:

0, 50, 160, 500 μM
Incubation Time:

24 h
Result:

Reduced the adhesion to ECM proteins and the tyrosine phosphorylation of several proteins in a concentration-dependent manner.
Inhibited the migration at 500 μM.

In Vivo

4-Hydroxycoumarin (10, 20 or 40 mg/kg/day, oral gavage) can effectively inhibit tumor growth and improve survival rate in melanoma mice^[3].
4-Hydroxycoumarin (5, 10, 25, 50 mg/kg/ day, Oral gavage) can significantly reduce symptoms in a rat model of trinitrobenzene sulfonic acid-induced colitis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse melanoma model^[3]
Dosage:

10, 20 or 40 mg/kg
Administration:

i.g.
Result:

Reduced >85% of the number of pulmonary tumors.
Diminished the tumor size from day 22 and increased survival time at 10 mg/kg/day.

Animal Model:

Rat colitis model ^[4]
Dosage:

5, 10, 25, 50 mg/kg
Administration:

p.o.
Result:

Reduced damage score and extension of the lesion at doses of 10 and 25 mg/kg.
Counteracted GSH content and reduced AP activity at a dose of 5 mg/kg.
Showed a good recovery of the intestinal cytoarchitecture at doses of 5 and 25 mg/kg.

Chemical Information

CAS No. 1076-38-6
Appearance Solid
Masse moléculaire 162.14
Formule C₉H₆O₃
Color White to off-white
SMILES

O=C1C=C(O)C2=CC=CC=C2O1
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (616.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.1674 mL

30.8368 mL

61.6736 mL

5 mM

1.2335 mL

6.1674 mL

12.3347 mL

10 mM

0.6167 mL

3.0837 mL

6.1674 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (12.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (12.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (12.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Mohammadi Ziarani G, et al. The molecular diversity scope of 4-hydroxycoumarin in the synthesis of heterocyclic compounds via multicomponent reactions. Mol Divers. 2019 Jan 29. doi: 10.1007/s11030-019-09918-7. [Content Brief]

[2]. Velasco-Velázquez MA, et al. 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility. Cancer Lett. 2003 Aug 20;198(2):179-86. [Content Brief]

[3]. Salinas-Jazmín N, et al. Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model. Cancer Chemother Pharmacol. 2010 Apr;65(5):931-40. [Content Brief]

[4]. Luchini AC, et al. Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. Biol Pharm Bull. 2008 Jul;31(7):1343-50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.1674 mL	30.8368 mL	61.6736 mL	154.1839 mL
	5 mM	1.2335 mL	6.1674 mL	12.3347 mL	30.8368 mL
	10 mM	0.6167 mL	3.0837 mL	6.1674 mL	15.4184 mL
	15 mM	0.4112 mL	2.0558 mL	4.1116 mL	10.2789 mL
	20 mM	0.3084 mL	1.5418 mL	3.0837 mL	7.7092 mL
	25 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	30 mM	0.2056 mL	1.0279 mL	2.0558 mL	5.1395 mL
	40 mM	0.1542 mL	0.7709 mL	1.5418 mL	3.8546 mL
	50 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	60 mM	0.1028 mL	0.5139 mL	1.0279 mL	2.5697 mL
	80 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	100 mM	0.0617 mL	0.3084 mL	0.6167 mL	1.5418 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

4-Hydroxycoumarin

Voir tous les produits spécifiques à Isoform Endogenous Metabolite